Stanford University


Showing 971-980 of 2,304 Results

  • Kiran Kaur Khush, MD

    Kiran Kaur Khush, MD

    Professor of Medicine (Cardiovascular Medicine)

    Current Research and Scholarly InterestsDr. Khush'’s clinical research interests include the evaluation of donors and recipients for heart transplantation; mechanisms of adverse outcomes after heart transplantation, including cardiac allograft vasculopathy and antibody-mediated rejection; and development of non-invasive diagnostic approaches for post-transplant monitoring.

  • Michaela Kiernan

    Michaela Kiernan

    Sr Research Scholar, Medicine - Med/Stanford Prevention Research Center

    Current Research and Scholarly InterestsResearch interests include: (1) the design and testing of targeted behavioral interventions that promote long-term lifestyle changes and weight management among subgroups at risk, and (2) the development of methodological and statistical approaches that improve the design, delivery, and analysis of behavioral randomized clinical trials

  • Joel Killen

    Joel Killen

    Professor (Research) of Medicine (General Internal Medicine), Emeritus

    Current Research and Scholarly InterestsMy research is focused on the development and evaluation of cigarette smoking prevention and cessation therapies and obesity prevention treatments for children, adolescents and adults.

  • Dan Seung Kim, MD, PhD, MPH

    Dan Seung Kim, MD, PhD, MPH

    Fellow in Medicine - Med/Cardiovascular Medicine

    Current Research and Scholarly InterestsMy research projects within the laboratory of Euan Ashley center around the broad topic of exercise, physiology, and cardiovascular disease:
    1. Digital health interventions - I previously have published on the topic of digital health interventions delivered via an iPhone app (Kim and Javed et al, European Heart Journal - Digital Health 2023). We found that personalizing interventions based on individual's baseline activity was more effective in increasing short-term physical activity than other "one-size fits all" approaches. In our next phase, we will extend this to under-represented populations in digital health and implement cutting-edge artificial intelligence models to improve our interventions.
    2. Molecular mechanisms of exercise physiologic adaptations - using time-series multi-omic data, we aim to map out the molecular responses to endurance exercise training in rats, using data from the Molecular Transducers of Physical Activity Consortium (MoTrPAC). See our recent review in Nature Reviews Genetics - Kim et al, 2021.
    3. Effect of physical activity on coronary artery disease symptoms and outcomes - in collaboration with Dr David Maron and the ISCHEMIA study, I am investigating the effects of physical activity and sedentary behavior on symptoms related to known coronary heart disease and separately, the outcome of all-cause mortality.
    4. Exercise [hysiology - in collaboration with Dr Francois Haddad and Dr Jonathan Myers, I am working on projects to better standardize reporting of maximal oxygen uptake. In brief, maximal oxygen uptake (VO2 max) is an extremely valuable prognostic, but estimation of this physiologic value is poor in certain populations. We are working to improve estimation of this variable and demonstrating its efficacy in predicting hard outcomes in patients with heart failure.
    5. Outcomes in inherited cardiomyopathies - under the mentorship of Dr Euan Ashley, I am building my clinical expertise in treating patients with inherited cardiomyopathies. The Stanford Center for Inherited Cardiovascular Disease (SCICD) is home to clinical care of patients with inherited cardiomyopathies, channelopathies, inherited lipid disorders, neuromuscular disorders (e.g., muscular dystrophy), and vascular disorders (e.g., Marfan's and other aorthopathies). Our clinic is nested within the Heart Failure program and manages those patients who are progressing toward advanced heart failure therapies, such as transplant or left ventricular assist devices. Within this clinic, I am leading projects to describe our experience with mavacamten, a first of its class treatment of hypertrophic cardiomyopathy with obstruction.